MarketInOut Stock Screener Log In | Sign Up

Faron Pharmaceuticals Oyj

LSE • Healthcare • Biotechnology • Quote as of 10/27/2026 14:16
Faron Pharmaceuticals Oyj stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeLSE
Market Capitalization64.96 mln
Float138 mln
Earnings Date03/04/2027

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

978.71
Transformational upside

Relative Strength

15 / 100
Significantly lagging

Debt / Equity

1.55
High leverage

ROE

476
Extraordinary

ROA

-71.34
Deeply negative

Business Description

Faron Pharmaceuticals, founded in 2003 and based in Turku, Finland, is a medical research company focused on developing new treatments for cancer and serious immune-related conditions. Its most advanced drug, bexmarilimab, works by reprogramming certain immune cells within tumors to help the body fight cancer more effectively, and is being tested in patients with blood cancers such as acute myeloid leukemia and myelodysplastic syndromes. The company is also researching how specific receptors in the body regulate immune responses, with potential applications in organ damage and bone marrow recovery.

Key Fundamentals

EPS-10.00
ROE476
ROIC-152
ROA-71.34
Interest Cover-8.09
EBITDA, mln-11.81
EV / EBITDA-3.89
EV / EBIT-3.80

Quote Details

Last 33.00
Change 1 (3.12%)
Open 32.20
Volume 20,018
Turnover 660,594
Average Volume 31,006

Financial Ratios

Leverage Ratio3.10
Current Ratio2.40
Price / Book7.76
Price / Tangible Book9.50
Debt / Equity1.55

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price978.71

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -7.3% 6 / 100   
1 Month -15.38% 6 / 100   
2 Months -17.87% 8 / 100   
6 Months -14.73% 14 / 100   
1 Year -82.81% 1 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog